Rare Diseases Today—June 11, 2026

This week’s Rare Diseases update highlights regulatory approvals, pediatric label expansions, orphan designations, and policy-driven access reforms across hematology, dermatology, metabolic, and neuromuscular rare conditions.

In Today’s Newsletter

Dive deeper

🩸 Pfizer expands HYMPAVZI use in hemophilia [1] [US • 08 Jun 2026]

https://www.pfizer.com/news/press-release/press-release-detail/us-fda-approves-pfizers-hympavzi-treatment-two-additional
Context: HYMPAVZI (Pfizer; marstacimab) is a once-weekly subcutaneous prophylactic therapy for hemophilia A or B.
Key point: FDA approved an expanded indication covering patients aged 12+ with inhibitors and children aged 6–11 years with or without inhibitors.
Implication: May influence prescriber choice and payer reviews pending full data.

🧴 Chiesi gains Health Canada Priority Review for FILSUVEZ [2] [Canada • 09 Jun 2026]

https://www.globenewswire.com/news-release/2026/06/09/3308760/0/en/chiesi-global-rare-diseases-announces-health-canada-grants-priority-review-for-filsuvez-birch-triterpenes-topical-gel-for-the-treatment-of-epidermolysis-bullosa.html
Context: FILSUVEZ (birch triterpenes topical gel) is under review for wounds associated with dystrophic and junctional epidermolysis bullosa.
Key point: Health Canada accepted the submission under Priority Review, shortening the review timeline versus standard review.
Implication: May influence prescriber choice and payer reviews pending full data.

🧬 EU approves pediatric LOJUXTA expansion [3] [EU • 05 Jun 2026]

https://www.globenewswire.com/news-release/2026/06/05/3307192/0/en/chiesi-global-rare-diseases-announces-european-commission-approval-of-lojuxta-lomitapide-capsules-for-paediatric-use-in-homozygous-familial-hypercholesterolaemia-hofh.html
Context: LOJUXTA (lomitapide) was previously approved in adults with homozygous familial hypercholesterolaemia (HoFH).
Key point: European Commission approval expands use to children aged 5 years and older with HoFH.
Implication: May influence prescriber choice and payer reviews pending full data.

🧒 FDA designations for GEn-1123 in Duchenne muscular dystrophy [4] [US • 09 Jun 2026]

https://www.contemporarypediatrics.com/view/fda-grants-gen-1123-rare-disease-designations-for-duchenne-muscular-dystrophy
Context: GEn-1123 (GEn1E Lifesciences) is an investigational oral small-molecule therapy for DMD.
Key point: FDA granted both orphan drug designation and rare pediatric disease designation.
Implication: Signals pipeline investment and modality expansion.

🇰🇷 South Korea moves to accelerate rare disease drug access [5] [South Korea • 08 Jun 2026]

https://www.koreabiomed.com/news/articleView.html?idxno=31933 Context: The Ministry of Health and Welfare plans a pilot reimbursement reform program.
Key point: The proposed framework would reduce reimbursement listing timelines for eligible rare disease medicines.
Implication: May expand screening, initiation, and follow-up at scale.

🧴 Japan grants orphan designation to QRX003 [6] [Japan • 04 Jun 2026]

https://investors.quoinpharma.com/news-releases/news-release-details/quoin-pharmaceuticals-announces-japans-mhlw-grants-orphan-drug
Context: QRX003 (Quoin Pharmaceuticals) is being developed for Netherton syndrome.
Key point: Japan’s MHLW granted orphan drug designation to the program.
Implication: Signals pipeline investment and modality expansion.

🫀 Attralus secures FDA orphan designation for AT-02 [7] [US • 04 Jun 2026]

https://attralus.com/press-releases/attralus-therapeutic-zamubafusp-alfa-at-02-receives-u-s-fda-orphan-drug-designation-for-the-treatment-of-al-amyloidosis
Context: Zamubafusp alfa (AT-02) is a pan-amyloid removal candidate being studied in AL amyloidosis.
Key point: FDA granted orphan drug designation for treatment of AL amyloidosis.
Implication: Signals pipeline investment and modality expansion.

📊 Azafaros publishes Phase 2 RAINBOW data [8] [04 Jun 2026]

https://www.businesswire.com/news/home/20260604044697/en/Azafaros-Announces-Publication-of-Phase-2-RAINBOW-Study-Data-for-Nizubaglustat-in-Molecular-Genetics-and-Metabolism-Journal
Context: The RAINBOW study evaluated nizubaglustat in GM2 gangliosidosis and Niemann-Pick type C disease.
Key point: Published Phase 2 data reported safety and tolerability, with reported reductions in disease progression and seizure burden.
Implication: May influence prescriber choice and payer reviews pending full data.

Why it matters

Regulatory activity remains strong across rare hematology, dermatology, metabolic, and neuromuscular diseases.
Pediatric rare disease populations continue to gain attention through label expansions and regulatory incentives.
Multiple orphan drug designations highlight ongoing investment in underserved indications.
Access and reimbursement reforms remain a key policy theme alongside drug development.
Late-stage and registrational programs continue to advance across several rare disease categories.

📚 View the full Rare Disease archive on our research hub page

🚀 Accelerate your success. Contact us now

📂 Explore our case studies. See examples of our work.

💡 Read our insights. Learn from our latest reports and analysis

🎬 Watch on YouTube. Subscribe and never miss a video.

🧰 See our full range of services. Discover how we can help you.

FAQ

What changed for HYMPAVZI in hemophilia?

Pfizer’s HYMPAVZI gained an expanded FDA indication covering additional hemophilia A and B populations, including pediatric patients and patients with inhibitors. [1]

What is FILSUVEZ seeking approval for in Canada?

Chiesi’s FILSUVEZ is under Priority Review for treatment of wounds associated with dystrophic and junctional epidermolysis bullosa. Approval remains under review. [2]

What does the LOJUXTA decision mean for HoFH?

The European Commission expanded lomitapide use to children aged 5 years and older with HoFH, alongside existing lipid-lowering approaches. [3]

What regulatory support did GEn-1123 receive?

GEn-1123 received FDA orphan drug designation and rare pediatric disease designation for Duchenne muscular dystrophy. Clinical development is ongoing. [4]

What is QRX003 being developed for?

Quoin Pharmaceuticals is developing QRX003 for Netherton syndrome, and the therapy has now received orphan designation in Japan. [6]

What did the RAINBOW study report for nizubaglustat?

Published Phase 2 data reported safety and tolerability, along with encouraging efficacy signals in GM2 gangliosidosis and Niemann-Pick type C disease. [8]

Entities / Keywords

Pfizer; HYMPAVZI; marstacimab; hemophilia A; hemophilia B; Chiesi Global Rare Diseases; FILSUVEZ; birch triterpenes; epidermolysis bullosa (EB); LOJUXTA; lomitapide; homozygous familial hypercholesterolaemia (HoFH); GEn1E Lifesciences; GEn-1123; Duchenne muscular dystrophy (DMD); Quoin Pharmaceuticals; QRX003; Netherton syndrome; Attralus; zamubafusp alfa; AT-02; AL amyloidosis; Azafaros; nizubaglustat; GM2 gangliosidosis; Niemann-Pick type C disease (NPC); rare disease reimbursement.